Evidence mapPaperPMID 40244378Full record

ReviewInternational journal of molecular sciences2025

MicroRNAs as Endocrine Modulators of Breast Cancer.

Vinitha Richard, Kevin Lee, Michael Joseph Kerin

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vinitha RichardDiscipline of Surgery, Lambe Institute for Translational Research, University of Galway, H91 V4AY Galway, Ireland.ORCID 0000-0002-5534-9205
Kevin LeeSchool of Medicine, University of Galway, H91 V4AY Galway, Ireland.
Michael Joseph KerinDiscipline of Surgery, Lambe Institute for Translational Research, University of Galway, H91 V4AY Galway, Ireland.

Funding

National Breast Cancer Research Institute (NBCRI) RGF019-2023
6 · The paper itself

Abstract

Breast cancer is an aggressive disease of multiple subtypes with varying phenotypic, hormonal, and clinicopathological features, offering enhanced resistance to conventional therapeutic regimens. There is an unmet need for reliable molecular biomarkers capable of detecting the malignant transformation from the early stages of the disease to enhance diagnosis and treatment outcomes. A subset of small non-coding nucleic acid molecules, micro ribonucleic acids (microRNAs/miRNAs), have emerged as promising biomarkers due to their role in gene regulation and cancer pathogenesis. This review discusses, in detail, the different origins and hormone-like regulatory functionalities of miRNAs localized in tumor tissue and in the circulation, as well as their inherent stability and turnover that determines the utility of miRNAs as biomarkers for disease detection, monitoring, prognosis, and therapeutic targets.

Indexed as

Breast NeoplasmsMicroRNAsAnimalsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorMicroRNAsbreast cancercanonical biogenesiscirculatory miRNAsexosomeshormone receptorsmicroRNAssystemic biomarkers

Identifiers

PMID40244378
PMCPMC11989600

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.